Lyell Immunopharma, Inc.

Spencer Park

Marc J Lajoie

Byoung Ryu

Queenie Vong

Blythe Sather

Scott Edward Boyken

Howell Franklin Moffett

Brian Weitzner

Yun Song

Neeraj Sharma

Shobha Potluri

Bijan Boldajipour

Disclosed herein are polynucleotides comprising a nucleotide sequence encoding an AP-1 transcription factor (i.e., c-Jun). In some aspects, the nucleotide sequence is codon-optimized. In some aspects, the polynucleotides comprise one or more additional nucleotide sequences encoding a linker, signal peptide, antigen-binding domain, spacer, transmembrane domain, costimulatory domain, intracellular signaling domain, truncated EGFR, and combinations thereof. Also disclosed herein are cells, vectors, and pharmaceutical compositions comprising such polynucleotides. The use of such polynucleotides, cells, vectors, and pharmaceutical compositions to treat a disease or disorder (e.g., cancer) is also provided.

Codon-optimized nucleotide sequences encoding an AP-1 transcription factor

The present disclosure relates to polynucleotides encoding a chimeric polypeptide comprising a c-Jun polypeptide, a ROR1-binding protein, and a truncated EGF receptor. Also provided are cells (e.g., T cells) expressing CARs comprising a ROR1-binding protein and overexpressing a c-Jun polypeptide. Overexpression of c-Jun in CAR T cells confers improved properties, e.g., reducing or preventing exhaustion.

ROR1 targeting chimeric antigen receptor

Growing community of inventors

Seattle, WA, United States of America

Spencer Park